-
1.发明公开POLY (ADP-RIBOSE) POLYMERASE 1 INHIBITORS STRUCTURALLY UNRELATED TO NAD 审中-公开POLY（ADP-RIBOSE）聚合酶1抑制剂结构上与NAD无关
公开(公告)号：EP3200792A2
公开(公告)日：2017-08-09
申请号：EP15847892.5
申请日：2015-09-30
发明人： TULIN, Alexei
IPC分类号： A61K31/4453 , A61P35/00 , C07D211/14
CPC分类号： C07D405/14 , A61P35/00 , C07D207/06 , C07D263/04 , C07D295/15 , C07D317/28 , C07D317/72 , C07D319/06 , C07D405/06 , C07D407/04
摘要： Compounds that are not related to NAD, and which target PARP1-histone H4 interaction are provided, as well as compositions of these compounds, and methods for specific inhibition of poly(ADP-ribose) polymerase 1 (PARP-1) using these compounds are provided. These PARP-1 inhibitors may be used to treat cancer in which PARP-1 activation or biologic activity plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
摘要翻译： 提供了与NAD无关并且靶向PARP1-组蛋白H4相互作用的化合物，以及这些化合物的组合物以及使用这些化合物特异性抑制聚（ADP-核糖）聚合酶1（PARP-1）的方法是 提供。 这些PARP-1抑制剂可用于治疗其中PARP-1活化或生物活性起作用的癌症，包括前列腺癌，乳腺癌，肾癌，卵巢癌，淋巴瘤，白血病和成胶质细胞瘤等。
-
公开(公告)号：EP3475451A1
公开(公告)日：2019-05-01
申请号：EP17821007.6
申请日：2017-06-26
IPC分类号： C12Q1/68 , G01N33/574
-
3.发明公开
公开(公告)号：EP2914259A1
公开(公告)日：2015-09-09
申请号：EP13785753.8
申请日：2013-10-18
申请人： Synta Pharmaceuticals Corp. , The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
IPC分类号： A61K31/401 , A61K31/4196 , A61K31/55 , A61P43/00
CPC分类号： A61K31/541 , A61K31/401 , A61K31/4196 , A61K31/4439 , A61K31/496 , A61K31/5377 , A61K31/55 , A61K45/06 , A61K2300/00
摘要： Provided are methods of treating polycystic kidney disease in a subject in need thereof, by administering to the subject in need thereof, an effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods of treating polycystic kidney disease by a compound of formula (I) in combination with additional therapeutic agents.
-
-
搜索结果
3 条记录 (耗时 0.02 秒)
